Jade Biosciences, Inc. Common Stock (JBIO)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 55
- Market Cap
- $1.2B
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
SentiSense also tracks daily options readings for Jade Biosciences, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Jade Biosciences, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.